Search

Your search keyword '"Holcombe, Chris"' showing total 348 results
Start Over Author "Holcombe, Chris"
348 results on '"Holcombe, Chris"'

1. Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)

Author

Bliss, Judith M., Tovey, Holly, Evans, Abigail, Holcombe, Chris, Horgan, Kieran, Mallon, Elizabeth, Vidya, Raghavan, Skene, Anthony, Dodson, Andrew, Hills, Margaret, Detre, Simone, Zabaglo, Lila, Banerji, Jane, Kilburn, Lucy, Morden, James P., Robertson, John F. R., Smith, Ian, and Dowsett, Mitch

Published
2023
Full Text
View/download PDF

2. Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study

Author

Dave, Rajiv V., Elsberger, Beatrix, Taxiarchi, Vicky P., Gandhi, Ashu, Kirwan, Cliona C., Kim, Baek, Camacho, Elizabeth M., Coles, Charlotte E., Copson, Ellen, Courtney, Alona, Horgan, Kieran, Fairbrother, Patricia, Holcombe, Chris, Kirkham, Jamie J., Leff, Daniel R., McIntosh, Stuart A., O’Connell, Rachel, Pardo, Ricardo, Potter, Shelley, Rattay, Tim, Sharma, Nisha, Vidya, Raghavan, and Cutress, Ramsey I.

Published
2023
Full Text
View/download PDF

4. Molecular profiling after short-term preoperative endocrine therapy to identify oestrogen receptor positive (ER+)/HER2+ early breast tumours with favourable prognosis.

Author

Bergamino Sirvén, Milana, primary, Lopez-Knowles, Elena, additional, Zhu, Xixuan, additional, Tovey, Holly, additional, Xiao, Hui, additional, Kilburn, Lucy, additional, Alataki, Anastasia, additional, Holcombe, Chris, additional, Skene, Anthony, additional, Smith, Ian E., additional, Robertson, John Forsyth Russell, additional, Bliss, Judith, additional, Schuster, Eugene F., additional, Dowsett, Mitchell, additional, and Cheang, Maggie Chon U, additional

Published
2024
Full Text
View/download PDF

6. HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer

Author

Evans, Abigail, Ball, Adrian, Johri, Akhil, Nejim, Ali, Jones, Alison, Corder, Allan, Thorne, Amanda, Anand, Ambika, Chakrabarti, Amitabha, Robinson, Anne, Skene, Anthony, Modi, Anupam, Patel, Ashraf, Kothari, Ashutosh, McFall, Brendan, Mortimer, Caroline, Lee, Caroline, Chan, Charlie, Abson, Charlotte, Holcombe, Christopher, Hinton, Christopher, Hollywood, Ciaran, Murphy, Claire, Crowley, Clare, Harding-Mackean, Claudia, Griffith, Clive, Lewanski, Conrad, Rea, Daniel, Hwang, David, Crawford, Derek, Thekkinkattil, Dinesh, Ferguson, Douglas, Adamson, Douglas, Wheatley, Duncan, Ravichandran, Duraisamy, Babu, Ed, Hyett, Elaine, Ashkanani, Fawzia, Hoar, Fiona, Kenny, Frances, Dyke, Gary, Sparrow, Geoffrey, Gilbert, Cunnick, Giles, Algurafi, Hafiz, Sweetland, Helen, Prof, Highes-Davies, Hamed, Hisham, Smith, Ian, Laidlaw, Ian, Khattak, Ilyas, Newby, Jacqueline, Rees-Lee, Jacqueline, Kokan, Jalal, Barrett, Jane, Naik, Jay Dolatrai, Vaidya, Jayant, Forrest, Jennifer, Parmar, Jitendra, Adams, Jocelyn, Fox, John, Roberts, Jonathan, Dawson, Jonathan, Doughty, Julie, Donnelly, Jull, Dunn, Kathleen, Chin, Kian, Horgan, Kieran, Thakur, Kislaya, Barthelmes, Ludger, Wyld, Lynda, Bhattacharyya, Madhumita, Hadaki, Maher, Kishore, Makam, Ornstein, Marcus, Bramley, Maria, Bews-Hair, Maria, Parton, Marina, Sibbering, Mark, Kissin, Mark, Churn, Mark, Hogg, Martin, Quigley, Mary, Hatton, Matthew, Winter, Matthew, Adelekan, Matthew, Shere, Michael, Carr, Michael, Williams, Michael, Absar, Mohammed, Sharif, Muhammad, Kelleher, Muireann, Walji, Nawaz, Williams, Nicholas, Gallegos, Nicholas, Bundred, Nigel, Hatcher, Olivia, Crellin, Perric, Crane, Peter, Donnelly, Peter, Kneeshaw, Peter, Walker, Philip, Sinha, Prakash, Bhaskar, Pudhupalayam, Soulsby, Racheal, Todd, Radha, Vidya, Raghavan, Mehra, Rakesh, Prasad, Ramachandran, Cutress, Ramsay, Sharma, Ravi, Roylance, Rebecca, Goranova, Rebecca, Salman, Reem Ramzi, Bonom, Riccardo, Johnson, Richard, Sutton, Richard, Linforth, Rick, Coleman, Rob, Grieve, Robert, Leonard, Robert, Reichert, Robert, Kennedy, Robert, Agarwal, Roshan, Allerton, Rozenn, Burcombe, Russell, Davis, Ruth, Narayanan, Sankaran, Chandrasekharan, Sankaran, Vesty, Sarah, Seetharam, Seema, Ledwidge, Serena, Iqbal, Shabana, Wahee, Shamaela, Silva, Shobha, Pain, Simon, Holt, Simon, Thomson, Simon, Smith, Simon, Ellenbogen, Simon, Laws, Siobhan, Chan, Stephen, Johnston, Stephen, Holt, Steve, Thrush, Steven, McIntosh, Stuart, Chatterjee, Sumohan, Cleator, Susan, Usman, Tamoor, Johnson, Tayo, Kovacs, Tibor, Irvine, Tracey, Barthkur, Urmila, Pope, Vanessa, Brown, Victoria Alexandra, Muralikrishna, Vummiti, Samra, Walid, Maxwell, William, Winters, Zoe, Bergamino, Milana A., López-Knowles, Elena, Morani, Gabriele, Tovey, Holly, Kilburn, Lucy, Schuster, Eugene F., Alataki, Anastasia, Hills, Margaret, Xiao, Hui, Holcombe, Chris, Robertson, John F., Smith, Ian E., Bliss, Judith M., Dowsett, Mitch, and Cheang, Maggie C.U.

Published
2022
Full Text
View/download PDF

7. Text mining and word embedding for classification of decision making variables in breast cancer surgery

Author

Heil, Joerg, Karakatsanis, Andreas, Weber, Walter Paul, Gonzalez, Eduardo, Chatterjee, Abhishek, Urban, Cicero, Sund, Malin, Paulinelli, Regis Resende, Markopoulos, Christos, Rubio, Isabel T., Masannat, Yazan A., Meani, Francesco, Koppiker, Chaitanyanand B., Holcombe, Chris, Benson, John R., Dietz, Jill R., Walker, Melanie, Mátrai, Zoltán, Shaukat, Ayesha, Gulluoglu, Bahadir, Brenelli, Fabricio, Fitzal, Florian, Mele, Marco, Kovacs, Tibor, Catanuto, G., Rocco, N., Maglia, A., Barry, P., Karakatsanis, A., Sgroi, G., Russo, G., Pappalardo, F., and Nava, M.B.

Published
2022
Full Text
View/download PDF

8. Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer

Author

Haynes, Ben P., Schuster, Gene, Buus, Richard, Alataki, Anastasia, Ginsburg, Ophira, Quang, Le Hong, Han, Pham Thi, Khoa, Pham Hong, Van Dinh, Nguyen, Van To, Ta, Clemons, Mark, Holcombe, Chris, Osborne, Caroline, Evans, Abigail, Skene, Anthony, Sibbering, Mark, Rogers, Clare, Laws, Siobhan, Noor, Lubna, Cheang, Maggie Chon U., Cleator, Susan J., Smith, Ian E., and Dowsett, Mitch

Published
2021
Full Text
View/download PDF

9. Observational cohort study to determine the degree and causes of variation in the rate of surgery or primary endocrine therapy in older women with operable breast cancer

Author

Lifford, Kate, Edwards, Adrian, Brain, Kate, Ring, Alistair, Robinson, Thomson, Chater, Tim, Pemberton, Kirsty, Shrestha, Anne, Nettleship, Anthony, Richards, Paul, Todd, Annaliza, Harder, Helena, Wright, Juliette, Simcock, Richard, Murray, Chris, Green, Tracy, Revill, Deirdre, Gath, Jacqui, Horgan, Kieran, Holcombe, Chris, Naik, Jay, Parmeshwar, Rishi, Morgan, Jenna L., Holmes, Geoff, Ward, Sue, Martin, Charlene, Burton, Maria, Walters, Stephen J., Cheung, Kwok Leung, Audisio, Riccardo A., Reed, Malcolm WR., and Wyld, Lynda

Published
2021
Full Text
View/download PDF

10. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial

Author

Smith, Ian, Robertson, John, Kilburn, Lucy, Wilcox, Maggie, Evans, Abigail, Holcombe, Chris, Horgan, Kieran, Kirwan, Cliona, Mallon, Elizabeth, Sibbering, Mark, Skene, Anthony, Vidya, Raghavan, Cheang, Maggie, Banerji, Jane, Morden, James, Sidhu, Kally, Dodson, Andrew, Bliss, Judith M, and Dowsett, Mitch

Published
2020
Full Text
View/download PDF

11. Understanding decision-making for and against oncoplastic breast-conserving surgery as an alternative to a mastectomy in early breast cancer: UK ANTHEM qualitative study.

Author

Davies, Charlotte, Conefrey, Carmel, Mills, Nicola, Fairbrother, Patricia, Holcombe, Chris, Whisker, Lisa, Skillman, Joanna, White, Paul, MacMillan, Douglas, Comins, Charles, Hollingworth, William, and Potter, Shelley

Subjects
MAMMAPLASTY, LUMPECTOMY, MASTECTOMY, BREAST cancer, DECISION making, QUALITATIVE research
Abstract

Background: Oncoplastic breast-conserving surgery may allow women with early breast cancer to avoid a mastectomy, but many women undergo more extensive surgery, even when breast-conserving options are offered. The aim of the ANTHEM qualitative study was to explore factors influencing women's surgical decision-making for and against oncoplastic breast-conserving surgery. Methods: Semi-structured interviews were conducted with a purposive sample of women who had received either oncoplastic breast-conserving surgery or a mastectomy with or without immediate breast reconstruction to explore their rationale for procedure choice. Interviews were transcribed verbatim and analysed thematically. Trial registration number: ISRCTN18238549. Results: A total of 27 women from 12 centres were interviewed. Out of these, 12 had chosen oncoplastic breast-conserving surgery and 15 had chosen a mastectomy with or without immediate breast reconstruction. Overwhelmingly, women's decisions were guided by their surgical teams. Decision-making for and against oncoplastic breast-conserving surgery was influenced by three key inter-related factors: perceptions of oncological safety; the importance of maintaining/restoring femininity and body image; and practical issues. Oncological safety was paramount. Women who reported feeling reassured that oncoplastic breast-conserving surgery was oncologically safe were happy to choose this option. Those who were not reassured were more likely to opt for a mastectomy, as a perceived 'safer' option. Most women wished to maintain/restore femininity, with the offer of immediate breast reconstruction essential to make a mastectomy an acceptable option. Practical issues such as the perceived magnitude of the surgery were a lesser concern. Conclusion: Decision-making is complex and heavily influenced by the surgical team. High-quality, accurate information about surgical options, including appropriate reassurance about the short- and long-term oncological safety of oncoplastic breast-conserving surgery is vital if women are to make fully informed decisions. Perceived overestimation of the oncological benefits of a mastectomy and a lack of awareness of the potential short- and long-term issues associated with breast reconstruction raise concerns about the quality of the information provided to women making decisions about their options and the degree to which their decisions are fully informed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Overall survival after mastectomy versus breast-conserving surgery with adjuvant radiotherapy for early-stage breast cancer: meta-analysis.

Author

Rajan, Kiran K, Fairhurst, Katherine, Birkbeck, Beth, Novintan, Shonnelly, Wilson, Rebecca, Savović, Jelena, Holcombe, Chris, and Potter, Shelley

Subjects
LUMPECTOMY, RADIOTHERAPY, BREAST cancer, MASTECTOMY, OVERALL survival, NEOADJUVANT chemotherapy
Abstract

Background Breast-conserving surgery with adjuvant radiotherapy and mastectomy are currently offered as equivalent surgical options for early-stage breast cancer based on RCTs from the 1970s and 1980s. However, the treatment of breast cancer has evolved and recent observational studies suggest a survival advantage for breast-conserving surgery with adjuvant radiotherapy. A systematic review and meta-analysis was undertaken to summarize the contemporary evidence regarding survival after breast-conserving surgery with adjuvant radiotherapy versus mastectomy for women with early-stage breast cancer. Methods A systematic search of MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL), and Embase that identified studies published between 1 January 2000 and 18 December 2023 comparing overall survival after breast-conserving surgery with adjuvant radiotherapy versus mastectomy for patients with unilateral stage 1–3 breast cancer was undertaken. The main exclusion criteria were studies evaluating neoadjuvant chemotherapy, rare breast cancer subtypes, and specific breast cancer populations. The ROBINS-I tool was used to assess risk of bias, with the overall certainty of evidence assessed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) tool. Studies without critical risk of bias were included in a quantitative meta-analysis. Results From 11 750 abstracts, 108 eligible articles were identified, with one article including two studies; 29 studies were excluded from the meta-analysis due to an overall critical risk of bias, 42 studies were excluded due to overlapping study populations, and three studies were excluded due to reporting incompatible results. A total of 35 observational studies reported survival outcomes for 909 077 patients (362 390 patients undergoing mastectomy and 546 687 patients undergoing breast-conserving surgery with adjuvant radiotherapy). The pooled HR was 0.72 (95% c.i. 0.68 to 0.75, P < 0.001), demonstrating improved overall survival for patients undergoing breast-conserving surgery with adjuvant radiotherapy. The overall certainty of the evidence was very low. Conclusion This meta-analysis provides evidence suggesting a survival advantage for women undergoing breast-conserving surgery with adjuvant radiotherapy for early-stage breast cancer compared with mastectomy. Although these results should be interpreted with caution, they should be shared with patients to support informed surgical decision-making. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Evidence-informed recommendations on managing breast screening atypia: perspectives from an expert panel consensus meeting reviewing results from the Sloane atypia project

Author

Freeman, Karoline, primary, Mansbridge, Alice, additional, Stobart, Hilary, additional, Clements, Karen, additional, Wallis, Matthew G, additional, Pinder, Sarah E, additional, Kearins, Olive, additional, Shaaban, Abeer M, additional, Kirwan, Cliona C, additional, Wilkinson, Louise S, additional, Webb, Sharon, additional, O’Sullivan, Emma, additional, Jenkins, Jacquie, additional, Wright, Suzanne, additional, Taylor, Kathryn, additional, Bailey, Claire, additional, Holcombe, Chris, additional, Wyld, Lynda, additional, Edwards, Kim, additional, Jenkinson, David J, additional, Sharma, Nisha, additional, Provenzano, Elena, additional, Hilton, Bridget, additional, Stallard, Nigel, additional, Thompson, Alastair M, additional, and Taylor-Phillips, Sian, additional

Published
2023
Full Text
View/download PDF

16. Wire- and radiofrequency identification tag-guided localization of impalpable breast lesions: iBRA-NET localization study.

Author

Harvey, James, Morgan, Jenna, Lowes, Simon, Milligan, Robert, Barrett, Emma, Carmichael, Amtul, Elgammal, Suzanne, Masudi, Tahir, Holcombe, Chris, Masannat, Yazan, Potter, Shelley, Dave, Rajiv V, Al Numani, H, Kastora, S, Simpson, L, Lynch, R, Kleidi, E, Wignarajah, P, Johnson, L, and Ledwidge, S

Subjects
RADIO frequency
Abstract

A national cohort ideal stage 2a/2b study comparing the safety and effectiveness of Wire- and RFID -guided localisation for impalpable breast lesions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Evidence-informed recommendations on managing breast screening atypia: perspectives from an expert panel consensus meeting reviewing results from the Sloane atypia project.

Author

Freeman, Karoline, Mansbridge, Alice, Stobart, Hilary, Clements, Karen, Wallis, Matthew G, Pinder, Sarah E, Kearins, Olive, Shaaban, Abeer M, Kirwan, Cliona C, Wilkinson, Louise S, Webb, Sharon, O'Sullivan, Emma, Jenkins, Jacquie, Wright, Suzanne, Taylor, Kathryn, Bailey, Claire, Holcombe, Chris, Wyld, Lynda, Edwards, Kim, and Jenkinson, David J

Subjects
BREAST, EARLY detection of cancer, EVIDENCE gaps, RESEARCH personnel, DATA integrity, MAMMOGRAMS
Abstract

Evidence-based clinical guidelines are essential to maximize patient benefit and to reduce clinical uncertainty and inconsistency in clinical practice. Gaps in the evidence base can be addressed by data acquired in routine practice. At present, there is no international consensus on management of women diagnosed with atypical lesions in breast screening programmes. Here, we describe how routine NHS breast screening data collected by the Sloane atypia project was used to inform a management pathway that maximizes early detection of cancer and minimizes over-investigation of lesions with uncertain malignant potential. A half-day consensus meeting with 11 clinical experts, 1 representative from Independent Cancer Patients' Voice, 6 representatives from NHS England (NHSE) including from Commissioning, and 2 researchers was held to facilitate discussions of findings from an analysis of the Sloane atypia project. Key considerations of the expert group in terms of the management of women with screen detected atypia were: (1) frequency and purpose of follow-up; (2) communication to patients; (3) generalizability of study results; and (4) workforce challenges. The group concurred that the new evidence does not support annual surveillance mammography for women with atypia, irrespective of type of lesion, or woman's age. Continued data collection is paramount to monitor and audit the change in recommendations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Long-term patient-reported outcomes of immediate breast reconstruction after mastectomy for breast cancer: population-based cohort study

Author

Johnson, Leigh, primary, White, Paul, additional, Jeevan, Ranjeet, additional, Browne, John, additional, Gulliver-Clarke, Carmel, additional, O’Donoghue, Joe, additional, Mohiuddin, Syed, additional, Hollingworth, William, additional, Fairbrother, Patricia, additional, MacKenzie, Mairead, additional, Holcombe, Chris, additional, and Potter, Shelley, additional

Published
2023
Full Text
View/download PDF

25. Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer

Author

Haynes, Ben P., Ginsburg, Ophira, Gao, Qiong, Folkerd, Elizabeth, Afentakis, Maria, Buus, Richard, Quang, Le Hong, Thi Han, Pham, Khoa, Pham Hong, Dinh, Nguyen Van, To, Ta Van, Clemons, Mark, Holcombe, Chris, Osborne, Caroline, Evans, Abigail, Skene, Anthony, Sibbering, Mark, Rogers, Clare, Laws, Siobhan, Noor, Lubna, Smith, Ian E., and Dowsett, Mitch

Published
2019
Full Text
View/download PDF

26. Correction: Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study

Author

Dave, Rajiv V., Kim, Baek, Courtney, Alona, O’Connell, Rachel, Rattay, Tim, Taxiarchi, Vicky P., Kirkham, Jamie J., Camacho, Elizabeth M., Fairbrother, Patricia, Sharma, Nisha, Cartlidge, Christopher W. J., Horgan, Kieran, McIntosh, Stuart A., Leff, Daniel R., Vidya, Raghavan, Potter, Shelley, Holcombe, Chris, Copson, Ellen, Coles, Charlotte E., Cutress, Ramsey I., Gandhi, Ashu, and Kirwan, Cliona C.

Published
2021
Full Text
View/download PDF

27. Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study

Author

Dave, Rajiv, Elsberger, Beatrix, Taxiarchi, Paraskevi, Gandhi, Ashu, Kirwan, Cliona, Kim, Baek, Camacho, Liz, Coles, Charlotte, Copson, Ellen, Courtney, Alona, Horgan, Kieran, Fairbrother, Patricia, Holcombe, Chris, Kirkham, Jamie, Leff, Daniel, McIntosh, Stuart, O’Connell, Rachel, Pardo, Ricardo, Potter, Shelley, Rattay, Tim, Sharma, Nisha, Vidya, Raghavan, and Cutress, Ramsey

Subjects
Breast cancer, SDG 3 - Good Health and Well-being, COVID-19, Neoadjuvant endocrine therapy, Bridging endocrine therapy
Abstract

Purpose: The B-MaP-C study investigated changes to breast cancer care that were necessitated by the COVID-19 pandemic. Here we present a follow-up analysis of those patients commenced on bridging endocrine therapy (BrET), whilst they were awaiting surgery due to reprioritisation of resources.Methods: This multicentre, multinational cohort study recruited 6045 patients from the UK, Spain and Portugal during the peak pandemic period (Feb-July 2020). Patients on BrET were followed up to investigate the duration of, and response to, BrET. This included changes in tumour size to reflect downstaging potential, and changes in cellular proliferation (Ki67), as a marker of prognosis.Results: 1094 patients were prescribed BrET, over a median period of 53 days (IQR 32-81 days). The majority of patients (95.6%) had strong ER expression (Allred score 7-8/8). Very few patients required expedited surgery, due to lack of response (1.2%) or due to lack of tolerance/compliance (0.8%). There were small reductions in median tumour size after 3 months' treatment duration; median of 4 mm [IQR - 20, 4]. In a small subset of patients (n = 47), a drop in cellular proliferation (Ki67) occurred in 26 patients (55%), from high (Ki67 ≥ 10%) to low (< 10%), with at least one month's duration of BrET.Discussion: This study describes real-world usage of pre-operative endocrine therapy as necessitated by the pandemic. BrET was found to be tolerable and safe. The data support short-term (≤ 3 months) usage of pre-operative endocrine therapy. Longer-term use should be investigated in future trials.

Published
2023

28. Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study

Author

Dave, Rajiv V, Elsberger, Beatrix, Taxiarchi, Vicky P, Gandhi, Ashu, Kirwan, Cliona C, Kim, Baek, Camacho, Elizabeth M, Coles, Charlotte E, Copson, Ellen, Courtney, Alona, Horgan, Kieran, Fairbrother, Patricia, Holcombe, Chris, Kirkham, Jamie J, Leff, Daniel R, McIntosh, Stuart A, O'Connell, Rachel, Pardo, Ricardo, Potter, Shelley, Rattay, Tim, Sharma, Nisha, Vidya, Raghavan, Cutress, Ramsey I, B-MaP-C Study Collaborative, Dave, Rajiv V [0000-0001-6827-8090], and Apollo - University of Cambridge Repository

Subjects
Cohort Studies, Ki-67 Antigen, Breast cancer, Humans, COVID-19, Female, Breast Neoplasms, Neoadjuvant endocrine therapy, Prognosis, Pandemics, Bridging endocrine therapy, Neoadjuvant Therapy
Abstract

PURPOSE: The B-MaP-C study investigated changes to breast cancer care that were necessitated by the COVID-19 pandemic. Here we present a follow-up analysis of those patients commenced on bridging endocrine therapy (BrET), whilst they were awaiting surgery due to reprioritisation of resources. METHODS: This multicentre, multinational cohort study recruited 6045 patients from the UK, Spain and Portugal during the peak pandemic period (Feb-July 2020). Patients on BrET were followed up to investigate the duration of, and response to, BrET. This included changes in tumour size to reflect downstaging potential, and changes in cellular proliferation (Ki67), as a marker of prognosis. RESULTS: 1094 patients were prescribed BrET, over a median period of 53 days (IQR 32-81 days). The majority of patients (95.6%) had strong ER expression (Allred score 7-8/8). Very few patients required expedited surgery, due to lack of response (1.2%) or due to lack of tolerance/compliance (0.8%). There were small reductions in median tumour size after 3 months' treatment duration; median of 4 mm [IQR - 20, 4]. In a small subset of patients (n = 47), a drop in cellular proliferation (Ki67) occurred in 26 patients (55%), from high (Ki67 ≥ 10%) to low (< 10%), with at least one month's duration of BrET. DISCUSSION: This study describes real-world usage of pre-operative endocrine therapy as necessitated by the pandemic. BrET was found to be tolerable and safe. The data support short-term (≤ 3 months) usage of pre-operative endocrine therapy. Longer-term use should be investigated in future trials.

Published
2023

29. Supplementary Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

Author

Robertson, John F.R., primary, Coleman, Robert E., primary, Cheung, Kwok-Leung, primary, Evans, Abigail, primary, Holcombe, Chris, primary, Skene, Anthony, primary, Rea, Daniel, primary, Ahmed, Samreen, primary, Jahan, Ali, primary, Horgan, Kieran, primary, Rauchhaus, Petra, primary, Littleford, Roberta, primary, Cheung, S.Y. Amy, primary, Cullberg, Marie, primary, de Bruin, Elza C., primary, Koulai, Loumpiana, primary, Lindemann, Justin P.O., primary, Pass, Martin, primary, Rugman, Paul, primary, Schiavon, Gaia, primary, Deb, Rahul, primary, Finlay, Pauline, primary, Foxley, Andrew, primary, and Gee, Julia M.W., primary

Published
2023
Full Text
View/download PDF

30. Abstract P2-03-07: Multi-parametric algorithm integrating on-treatment Ki67 value and standard clinicopathological variables to predict risk of recurrences for women &gt; 70 years old with early ER+HER2- tumours in POETIC trial

Author

Cheang, Maggie Chon U, primary, Dewan, Monisha, additional, Kilburn, Lucy, additional, Morani, Gabriele, additional, Zabaglo, Lila, additional, Sidhu, Kally, additional, Tovey, Holly, additional, Zhu, Xixuan, additional, Holcombe, Chris, additional, Skene, Anthony, additional, Smith, Ian, additional, Robertson, John, additional, Ring, Alistair, additional, Turner, Nicholas, additional, Bliss, Judith, additional, and Dowsett, Mitch, additional

Published
2023
Full Text
View/download PDF

31. Abstract PD15-10: PD15-10 Impact of procedure type on long-term revisional surgery and secondary reconstruction following immediate breast reconstruction: The UK Brighter national population-based cohort study

Author

Johnson, Leigh, primary, White, Paul, additional, Jeevan, Ranjeet, additional, Browne, John, additional, Gulliver-Clarke, Carmel, additional, O’Donoghue, Joe, additional, Mohiuddin, Syed, additional, Hollingworth, William, additional, Fairbrother, Patricia, additional, MacKenzie, Mairead, additional, Holcombe, Chris, additional, and Potter, Shelley, additional

Published
2023
Full Text
View/download PDF

33. Abstract PD15-09: PD15-09 Impact of procedure type on the long-term patient-reported outcomes of immediate breast reconstruction: The UK Brighter Study

Author

Johnson, Leigh, primary, White, Paul, additional, Jeevan, Ranjeet, additional, Browne, John, additional, Gulliver-Clarke, Carmel, additional, O’Donoghue, Joe, additional, Mohiuddin, Syed, additional, Hollingworth, William, additional, Fairbrother, Patricia, additional, MacKenzie, Mairead, additional, Holcombe, Chris, additional, and Potter, Shelley, additional

Published
2023
Full Text
View/download PDF

34. Abstract P2-03-08: Deconstructing the molecular characteristics of ER+ HER2+ early breast cancer in the POETIC trial using multiplex immunofluorescence and gene expression profiles

Author

Zhu, Xixuan, primary, Xiao, Hui, additional, López-Knowles, Elena, additional, Sirvén, Milana A. Bergamino, additional, Alataki, Anastasia, additional, Maxwell, Perry, additional, Tovey, Holly, additional, Kilburn, Lucy, additional, Holcombe, Chris, additional, Skene, Anthony, additional, Smith, Ian, additional, Robertson, John, additional, Hoadley, Katherine A, additional, Salgado, Roberto, additional, Bliss, Judith, additional, Turner, Nicholas, additional, Salto-Tellez, Manuel, additional, Schuster, Gene, additional, Dowsett, Mitch, additional, and Cheang, Maggie Chon U, additional

Published
2023
Full Text
View/download PDF

35. Abstract P2-15-03: Impact of radiotherapy on the long-term patient-reported outcomes of immediate breast reconstruction: The UK Brighter

Author

Johnson, Leigh, primary, White, Paul, additional, Jeevan, Ranjeet, additional, Browne, John, additional, Gulliver-Clarke, Carmel, additional, O’Donoghue, Joe, additional, Mohiuddin, Syed, additional, Hollingworth, William, additional, Fairbrother, Patricia, additional, MacKenzie, Mairead, additional, Holcombe, Chris, additional, and Potter, Shelley, additional

Published
2023
Full Text
View/download PDF

36. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial

Author

Forbes, John F, Sestak, Ivana, Howell, Anthony, Bonanni, Bernardo, Bundred, Nigel, Levy, Christelle, von Minckwitz, Gunter, Eiermann, Wolfgang, Neven, Patrick, Stierer, Michael, Holcombe, Chris, Coleman, Robert E, Jones, Louise, Ellis, Ian, and Cuzick, Jack

Published
2016
Full Text
View/download PDF

37. The TeaM (Therapeutic Mammaplasty) study: Protocol for a prospective multi-centre cohort study to evaluate the practice and outcomes of therapeutic mammaplasty

Author

Baker, Elizabeth, Kim, Baek, Rattay, Tim, Williams, Kathryn, Ives, Charlotte, Remoundos, Dennis, Holcombe, Chris, Gardiner, Matthew D., Jain, Abhilash, Sutton, Richard, Achuthan, Rajgopal, Turton, Philip, Fairbrother, Patricia, Brock, Lisa, Aggarwal, Shweta, Basu, Naren, Murphy, John, Trickey, Adam, Macmillan, R. Douglas, and Potter, Shelley

Published
2016
Full Text
View/download PDF

38. Additional file 3 of Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)

Author

Bliss, Judith M., Tovey, Holly, Evans, Abigail, Holcombe, Chris, Horgan, Kieran, Mallon, Elizabeth, Vidya, Raghavan, Skene, Anthony, Dodson, Andrew, Hills, Margaret, Detre, Simone, Zabaglo, Lila, Banerji, Jane, Kilburn, Lucy, Morden, James P., Robertson, John F. R., Smith, Ian, and Dowsett, Mitch

Abstract

Additional file 3: Fig. S3. Log fold change in Ki67 A. for patients allocated control by sample. type, B. for patients allocated AI by sample type and choice of AI. Presented separately for HER2- and HER2- patients.

Published
2023
Full Text
View/download PDF

39. Additional file 1 of Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)

Author

Bliss, Judith M., Tovey, Holly, Evans, Abigail, Holcombe, Chris, Horgan, Kieran, Mallon, Elizabeth, Vidya, Raghavan, Skene, Anthony, Dodson, Andrew, Hills, Margaret, Detre, Simone, Zabaglo, Lila, Banerji, Jane, Kilburn, Lucy, Morden, James P., Robertson, John F. R., Smith, Ian, and Dowsett, Mitch

Abstract

Additional file 1: Fig. S1. Distribution of Ki67Baseline a. Distribution of Ki67 % positive cells b. Distribution of ln(Ki67+0.1) c. Distribution of Ki67Baseline by HER2 status

Published
2023
Full Text
View/download PDF

40. Additional file 2 of Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)

Author

Bliss, Judith M., Tovey, Holly, Evans, Abigail, Holcombe, Chris, Horgan, Kieran, Mallon, Elizabeth, Vidya, Raghavan, Skene, Anthony, Dodson, Andrew, Hills, Margaret, Detre, Simone, Zabaglo, Lila, Banerji, Jane, Kilburn, Lucy, Morden, James P., Robertson, John F. R., Smith, Ian, and Dowsett, Mitch

Abstract

Additional file 2: Fig. S2. Distribution of A. log(Ki67Baseline +0.1) for all patients, B. log(Ki672week +0.1) in patients allocated control, C. log fold. change Ki67 in patients allocated control, D. log(Ki672week +0.1) in patients allocated AI and E. log fold change Ki67 in patients allocated AI. Presented separately for HER2- and HER2+ patients.

Published
2023
Full Text
View/download PDF

41. Additional file 4 of Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)

Author

Bliss, Judith M., Tovey, Holly, Evans, Abigail, Holcombe, Chris, Horgan, Kieran, Mallon, Elizabeth, Vidya, Raghavan, Skene, Anthony, Dodson, Andrew, Hills, Margaret, Detre, Simone, Zabaglo, Lila, Banerji, Jane, Kilburn, Lucy, Morden, James P., Robertson, John F. R., Smith, Ian, and Dowsett, Mitch

Abstract

Additional file 4: Table S1. Univariable and multivariable linear regression results for change in Ki67 in patients allocated to control by HER2 status. Table S2. Multivariable linear regression results for change in Ki67 in patients allocated to control by HER2 status showing adjustment for sample type. Table S3. Multivariable linear regression results for change in Ki67 in patients allocated to AI by HER2 status showing adjustment for sample type and AI choice. Table S4. CCCA by AI and sample type in patients allocated AI.

Published
2023
Full Text
View/download PDF

42. Helicobacter pylori : its role in the aetiology of non-ulcer dyspepsia in northern Nigeria

Author

Holcombe, Chris

Subjects
616.3
Abstract

In a pilot study dyspepsia was found to account for 20/1,000 admissions at the University of Maiduguri Teaching Hospital, in Northern Nigeria, the majority of these patients had non-ulcer dyspepsia. In a prospective study of patients presenting with carefully defined non-ulcer dyspepsia 53 of 57 patients had gastritis and of these 46/53 (87%) were infected by the bacteria Helicobacter pylori (H.pvlori). As a result of this pilot study and a subsequent review of the literature it was hypothesised that H.pvlori is the cause of non-ulcer dyspepsia in northern Nigeria. The strong association of H.pylori with non-ulcer dyspepsia was confirmed in a prospective study of 138 patients, 126 (91%) of whom had gastritis and of these 120 (95%) were infected by H.pvlori. However this high prevalence of H.pvlori infection must be judged against the prevalence of infection in the general population. In a random serological survey 228/268 (85%) subjects over 5 years had IgG antibodies to H.pylori. This is not significantly different from that found in patients with nonulcer dyspepsia (87%). H.pvlori infection was also present in 80% of 40 asymptomatic volunteers. H.pvlori acting alone does not cause non-ulcer dyspepsia, but may play a role in combination with other factors. If this is the case, clearance of the organism should lead to improvement or resolution of symptoms. Therefore 130 patients were entered into a therapeutic trial of a combination antacid (Gelusil) one tablet four times a day versus an anti-H.pylori regime (DeNol 240 mg four times a day and amoxycillin, 500mg four times a day for the first 14 days). One hundred and nine patients were reassessed at the end of treatment. Symptoms completely resolved in 1 of 23 patients (4.4%) who had taken Gelusil and 28 of 86 (32%) of patients who had taken bismuth & amoxycillin, a statistically significant difference (p<0.01). However, resolution of symptoms was not related to H.pvlori clearance. These studies do not provide any evidence to support a role for H.pvlori in the cause of non-ulcer dyspepsia in northern Nigeria, thus disproving the hypothesis.

Published
1992

43. Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

Author

Robertson, John F.R., primary, Coleman, Robert E., additional, Cheung, Kwok-Leung, additional, Evans, Abigail, additional, Holcombe, Chris, additional, Skene, Anthony, additional, Rea, Daniel, additional, Ahmed, Samreen, additional, Jahan, Ali, additional, Horgan, Kieran, additional, Rauchhaus, Petra, additional, Littleford, Roberta, additional, Amy Cheung, S.Y., additional, Cullberg, Marie, additional, de Bruin, Elza C., additional, Koulai, Loumpiana, additional, Lindemann, Justin P.O., additional, Pass, Martin, additional, Rugman, Paul, additional, Schiavon, Gaia, additional, Deb, Rahul, additional, Finlay, Pauline, additional, Foxley, Andrew, additional, and Gee, Julia M.W., additional

Published
2022
Full Text
View/download PDF

46. Text mining and word embedding for classification of decision making variables in breast cancer surgery

Author

Catanuto, G., primary, Rocco, N., additional, Maglia, A., additional, Barry, P., additional, Karakatsanis, A., additional, Sgroi, G., additional, Russo, G., additional, Pappalardo, F., additional, Nava, M.B., additional, Heil, Joerg, additional, Karakatsanis, Andreas, additional, Weber, Walter Paul, additional, Gonzalez, Eduardo, additional, Chatterjee, Abhishek, additional, Urban, Cicero, additional, Sund, Malin, additional, Paulinelli, Regis Resende, additional, Markopoulos, Christos, additional, Rubio, Isabel T., additional, Masannat, Yazan A., additional, Meani, Francesco, additional, Koppiker, Chaitanyanand B., additional, Holcombe, Chris, additional, Benson, John R., additional, Dietz, Jill R., additional, Walker, Melanie, additional, Mátrai, Zoltán, additional, Shaukat, Ayesha, additional, Gulluoglu, Bahadir, additional, Brenelli, Fabricio, additional, Fitzal, Florian, additional, Mele, Marco, additional, and Kovacs, Tibor, additional

Published
2022
Full Text
View/download PDF

47. Impact of procedure type on revisional surgery and secondary reconstruction after immediate breast reconstruction in a population-based cohort.

Author

Johnson, Leigh, White, Paul, Holcombe, Chris, O'Donoghue, Joe, Jeevan, Ranjeet, Browne, John, Fairbrother, Patricia, MacKenzie, Mairead, Gulliver-Clarke, Carmel, Mohiuddin, Syed, Hollingworth, Will, and Potter, Shelley

Subjects
MAMMAPLASTY, FREE flaps, CARCINOMA in situ, DUCTAL carcinoma, HOSPITAL statistics, SURGERY
Abstract

Background: Women considering immediate breast reconstruction require high-quality information about the likely need for secondary reconstruction and the long-term risk of revisional surgery to make fully informed decisions about different reconstructive options. Such data are currently lacking. This study aimed to explore the impact of reconstruction type on the number of revisions and secondary reconstructions performed 3, 5, and 8 years after immediate breast reconstruction in a large population-based cohort. Methods: Women undergoing unilateral mastectomy and immediate breast reconstruction for breast cancer or ductal carcinoma in situ in England between 1 April 2009 and 31 March 2015 were identified from National Health Service Hospital Episode Statistics. Numbers of revisions and secondary reconstructions in women undergoing primary definitive immediate breast reconstruction were compared by procedure type at 3, 5, and 8 years after index surgery. Results: Some 16 897 women underwent immediate breast reconstruction with at least 3 years' follow-up. Of these, 14 069 had a definitive reconstruction with an implant only (5193), latissimus dorsi flap with (3110) or without (2373) an implant, or abdominal free flap (3393). Women undergoing implant-only reconstruction were more likely to require revision, with 69.5 per cent (747 of 1075) undergoing at least one revision by 8 years compared with 49.3 per cent (1568 of 3180) in other reconstruction groups. They were also more likely to undergo secondary reconstruction, with the proportion of women having further reconstructive procedures increasing over time: 12.8 per cent (663 of 5193) at 3 years, 14.3 per cent (535 of 3752) at 5 years, and 17.6 per cent (189 of 1075) at 8 years. Conclusion: Long-term rates of revisions and secondary reconstructions were considerably higher after primary implant-based reconstruction than autologous procedures. These results should be shared with patients to support informed decision-making. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. Improving outcomes for women aged 70 years or above with early breast cancer: research programme including a cluster RCT

Author

Wyld, Lynda, primary, Reed, Malcolm WR, additional, Collins, Karen, additional, Ward, Sue, additional, Holmes, Geoff, additional, Morgan, Jenna, additional, Bradburn, Mike, additional, Walters, Stephen, additional, Burton, Maria, additional, Lifford, Kate, additional, Edwards, Adrian, additional, Brain, Kate, additional, Ring, Alistair, additional, Herbert, Esther, additional, Robinson, Thompson G, additional, Martin, Charlene, additional, Chater, Tim, additional, Pemberton, Kirsty, additional, Shrestha, Anne, additional, Nettleship, Anthony, additional, Richards, Paul, additional, Brennan, Alan, additional, Cheung, Kwok Leung, additional, Todd, Annaliza, additional, Harder, Helena, additional, Audisio, Riccardo, additional, Battisti, Nicolo Matteo Luca, additional, Wright, Juliet, additional, Simcock, Richard, additional, Murray, Christopher, additional, Thompson, Alastair M, additional, Gosney, Margot, additional, Hatton, Matthew, additional, Armitage, Fiona, additional, Patnick, Julietta, additional, Green, Tracy, additional, Revill, Deirdre, additional, Gath, Jacqui, additional, Horgan, Kieran, additional, Holcombe, Chris, additional, Winter, Matt, additional, Naik, Jay, additional, and Parmeshwar, Rishi, additional

Published
2022
Full Text
View/download PDF

49. Long-term patient-reported outcomes of immediate breast reconstruction: Initial results from the brighter study

Author

Johnson, Leigh, primary, White, Paul, additional, Jeevan, Ranjeet, additional, Browne, John, additional, Gulliver-Clarke, Carmel, additional, O'Donoghue, Joe, additional, Mohiuddin, Syed, additional, Hollingworth, Will, additional, Fairbrother, Patricia, additional, MacKenzie, Mairead, additional, Holcombe, Chris, additional, and Potter, Shelley, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results